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Abstract
Introduction: Serum CA15-3 has been one of the most reliable tumor markers used in monitoring of breast 
cancer patients. To increase its sensitivity, the combined measurement of other tumor markers (CEA and fer-
ritin) with CA15-3 was investigated. The aim of this study was determination of CA 15-3, CEA and ferritin in 
female patients with breast cancer, lung cancer and mastitis
Methods: 300 patients with carcinoma, hospitalized at Department of Gynecologic Oncology and Depart-
ment for Oncology at the University Clinics Center of Sarajevo and 200 healthy subjects were compared. 
Results: In patients with breast cancer the mean value of tumor markers were CEA 155.61 ng/mL, CA 15-3 
106.38 U/mL and ferritin 197.03 ng/mL. In patients with lung cancer CEA was 58.97 ng/ml, CA 15-3 40.62 U/
mL and ferritin 544.16 ng/mL. Patients with mastitis had CEA 5.17 ng/mL, CA 15-3 112.67 U/mL and ferritin 
174.92 ng/mL. The control group had values of tumor markers CEA 1.62 ng/mL, CA 15-3 11.72 U/mL and fer-
ritin 85.35 ng/mL. We found good correlation between CA 15-3 and CEA correlation coeffi cient was r = 0.750. 
There was a low correlation between CA 15-3 and ferritin with correlation coeffi cient r = 0.274. 
Conclusions: The CA 15-3 and CEA are useful markers in patients with confi rmed diagnosis of breast and 
lung cancers. The ferritin concentration has not increased in patients with breast cancer but it increased in 
lung patients. The future study has to make investigations of tumor markers and ferritin in different stage of 
breast cancer.  © 2012 All rights reserved
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Introduction
Although the measurement of tumor markers 
in breast cancer has been studied for nearly 20 
years, their usefulness remains unclear. In pa-
tients with metastatic breast carcinoma, tumor 
markers appear to be useful during follow-up, 
but a wide range in rates of marker positivity has 
been reported: 50%–80% (1-3). Breast cancer is 
the most common malignancy in women. Suc-
cessful treatment of breast cancer relies on a bet-
ter understanding of the molecular mechanisms 
involved in breast cancer initiation and progres-
sion (4). Th e CA 15-3 concentrations increase was 
observed in various malignant tumors, but this is 
a useful marker for breast cancer metastasis and 
is determined in monitoring disease progression 
and success of therapy. It is not used as screening 
test or as a test for primary diagnosis because it 
has low diagnostic sensitivity (5). CA 15-3 alone, 
however, is not recommended as a marker for ei-
ther diagnosis or detection of early recurrence of 
breast cancer according to the American Society 
of Clinical Oncology (ASCO) guidelines (6). Be-
cause of insuffi  cient data, the ASCO also does not 
recommend the use of CA 15-3 alone as a marker 
for monitoring response. It should be noted that 
the elevation of CA 15-3 between 4 and 6 weeks 
aft er initiation of a new therapy, i.e. spurious early 
rise (surge), indicates poor prognosis. Th e propor-
tion of patients exhibiting a surge in CA 15-3 level 
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aft er chemotherapy initiation was reported to be 
4.8%, and patients with surge may respond more 
poorly to chemotherapy than those without surge 
(7). CEA is also not recommended as a marker for 
diagnosis or routine surveillance aft er primary 
therapy, and a surge in CEA level may also occur 
between 4 and 6 weeks aft er initiation of primary 
treatment. Th e ASCO does not recommend CEA 
measurement in patients with positive CA 15-3; 
thus, the CEA level provides only supplementary 
information. However, if suffi  cient data regarding 
other factors are available, rising CEA level can 
be a useful indicator of treatment failure in pa-
tients without measurable disease (8). Eff orts are 
directed to identify new markers of breast cancer, 
which might be used for early detection, staging 
and prognosis, and prediction of therapy response. 
Ferritin is a large macromolecule (450 kDa) which 
is synthesized in the liver, spleen, myocardium, 
placenta and other tissues and plays a major role 
in iron storage. It consists of 24 subunits which 
form protein shell (apoferritin) around an in-
soluble core of stored iron. Th ere are two types 
of subunits, the basic L and acidic H type. Dif-
ferent isoferritins have diff erent proportions of 
these two subunits (9). Ferritin is a sensitive in-
dicator of iron defi ciency, thus the main clinical 
application of serum ferritin measurement is in 
diff erential diagnosis of anaemia. Ferritin con-
centration may increase in case of iron overload 
(haemochromatosis or haemosiderosis), infection 
or infl ammation, neurodegenerative disorders, 
malignancies and destruction of liver tissue (10).
Ferritin is one of the proteins whose concentration 
may be altered due to breast cancer presence. Re-
cent studies have suggested a crucial role of per-
turbations in ferritin levels and tightly associated 
with this, the deregulation of intracellular iron 
homeostasis; however, the underlying molecular 
mechanisms for the cancer-linked ferritin altera-
tions remain largely unknown and oft en with con-
fl icting conclusions (11). Th erefore, this study was 
undertaken to defi ne the role of ferritin in breast 
cancer. We have make determination of CA 15-3, 
CEA and ferritin at patents with breast or lung 
cancer and patients with diagnosis of mastitis. At 
our investigation we try to fi nd a possible correla-
tion between tumor marker CA 15-3 with tumor 
marker CEA and ferritin in patients with cancer.
Methods
Patients
Th e investigation included patients (n= 500) in pe-
riod from February till October in 2011. It was ret-
rospective study ant we included female patients 
with diagnosis breast cancer, lung cancer or with 
diagnosis of mastitis. All of 300 patients were hos-
pitalized at Department of Gynecologic Oncology 
and Department for Oncology at the University 
Clinics Center of Sarajevo and 200 healthy sub-
jects. Th e mean age of patients with cancer was 
45.32-/+ 9.23, patents with mastitis 35.24 +/- 5.64 
and mean age of control group was 43.45 -/+ 2.85.
Th e patient samples of blood were collected in 
serum separation Vacutainer test tubes (Beckton 
Dickinson, Rutherford, NJ 07,070 U.S.) in volume of 
3.5 mL. We used test tubes with gel. Serum samples 
were obtained by centrifugation at 3000 rpm using 
centrifuge (Sigma 4-10). Aft er centrifuging, serum 
concentration of CEA, CA 15-3 and ferritin was 
determined. Th e investigation was done respect-
ing ethical standards in the Helsinki Declaration. 
Chemiluminescent microparticle immunoassay – 
CMIA
All immunoassays require the use of labeled ma-
terial in order to measure the amount of anti-
gen or antibody. A label is a molecule that will 
react as a part of the assay, so a change in signal 
can be measured in the blood aft er added re-
agent solution. CMIA is noncompetitive sand-
wich assay technology to measure analytes. Th e 
amount of signal is directly proportional to 
the amount of analyte present in the sample.
Architect ferritin, CEA and CA 15-3 assay is two-
step immunoassay to determine the presence 
antigen in human serum using CMIA technol-
ogy. In the fi rst step, sample, assay diluent and 
anti-antibody-coated paramagnetic particles are 
combined. Ferritin, CEA or CA 15-3 present in 
the sample binds to the anti-coated micro parti-
cles. Aft er incubation and wash, anti-acridinium-
labeled conjugate is added in the second step. Fol-
lowing another incubation and wash, pre-trigger 
and trigger solutions are then added to the reac-
tion mixture. Th e pre-trigger solution (hydro-
gen peroxide) performs the following functions:
• Creates an acidic environment to prevent 
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early release of energy (light emission).
• Helps to keep microparticles from clumping.
•  Splits acridinium dye off  the conjugate bound 
to the microparticle complex. Th is action 
prepares the acridinium dye for the next step.
Th e trigger solution (sodium hydroxide) dis-
penses to the reaction mixture. Th e acridinium 
undergoes an oxidative reaction when exposed 
to peroxide and an alkaline solution. Th is reac-
tion causes the chemiluminescent reaction to oc-
cor. N-methylacridone forms and releases energy 
(light emission) as it returns to its ground state.
Th e resulting chemiluminescent reaction is mea-
sured as relative light units (RLU). A direct rela-
tionship exists between the amount of ferritin, 
CEA or CA 15-3 in the sample and RLU detected 
by Architect System optics (8). Th e normal serum 
range of CA 15-3 between 0. 0 – 31.3 U/mL, CEA 
0-5.00 ng/mL and ferritin 4.63 – 204.00 ng/mL. 
Statistical analysis
Th e results were statistically analyzed using NCSS 
and statistical soft ware SPSS version 12.0 soft ware. 
Determined by the average value ( ), standard 
deviation (SD), Pearson correlation coeffi  cient 
(r), equations of linear regression and Student t 
test with statistical signifi cance level of p <0.05.
Results
Th e CA 15-3 is cancer antigen that is used in the 
management of some patients with breast can-
cer. It is most eff ective at monitoring metastatic 
breast cancer, but has not had high success at 
detecting early stage breast cancers. Many stud-
ies are still conducted with the purpose of fi nd-
ing markers that could be used for early diagno-
sis and/or serve as possible reliable prognostic 
or predictive parameters, but with confl icting 
results. At present, no markers are available for 
an early diagnosis of breast cancer. Th e surveil-
lance of patients with diagnosed breast cancer 
the most widely used serum markers are CA 15-3 
and CEA which, in combination with other clini-
cal parameters, could have clinical signifi cance. 
Th e raised of serum ferritin concentrations in 
breast carcinoma patients might be attributed to 
stromal reaction rather than to tumor synthesis. 
In our study we have a female patients with diag-
nosis of breast and lung cancer. Th e patients with 
lung cancer have a primary cancer in breast. Th e 
patients with cancer were hospitalized in Depart-
ment of Gynecologic Oncology and Department 
for Oncology at the University Clinics Center of 
Sarajevo. Th e patients with mastitis were hos-
pitalized in Department of Gynecologic at the 
University Clinics Center of Sarajevo. Th e per-
cent of patients in our study is show in Figure 1. 
Abnormal CEA (>5 ng/mL) or CA 15.3 (>30 U/
mL) serum concentrations were found in 15.4% 
and 27.2 % of the patients studied, respectively. In 
patients with breast cancer the mean value of tumor 
markers were CEA 155.61 ng/mL, CA 15-3 106.38 
U/mL and ferritin 197.03 ng/mL. Our study have 
got results in patient with lung cancer CEA 58.97 
ng/ml, CA 15-3 40.62 U/mL and ferritin 544.16 
ng/mL. Th e results of our study have shown that 
the patients with mastitis have CEA 5.17 ng/mL, 
CA 15-3 112.67 U/mL and ferritin 174.92 ng/mL. 
Th e control groups have value of tumor markers 
CEA 1.62 ng/mL, CA 15-3 11.72 U/mL and ferri-
tin 85.35 ng/mL. Serum levels for the three tumor 
markers in patients with metastatic diseases were 
signifi cantly higher than those in patients without 
metastasis. Th is suggests that serum CA15-3 is the 
most reliable monitoring marker in patients with 
metastatic diseases. Th e CEA and ferritin were 
high in patients with lung cancer then CA 15-3 and 
it could be explain that CEA is more specifi c for 
lungs then CA 15-3. Th e raises serum ferritin in tu-
mors might be due to tumor synthesis because the 
ferritin is reactant of acute phase. Th e mean value 
of tumor marker in our study is shown in Figure 2. 
We compared CA 15-3 and ferritin in patients with 
FIGURE 1.  The patient diagnosis involved in the study
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cancer in 200 blood samplers (r = 0.274), results is 
shown in Figure 3. Regression equation revealed 
a slope of 0.5597 and a y axis intercept of 264.64. 
Th e diff erence between the tumor marker CA 15-3 
and ferritin was statistically signifi cant for p <0.05 
according Student t-test. Th e low correlation (r = 
0.274) was found between CA 15-3 and ferritin. 
Th e results of our comparison CA 15-3 and CEA are 
shown in Figure 4. Regression equation revealed 
a slope of 1.4334 and a y axis intercept of 118.39, 
correlation coeffi  cient was r = 0.75. Th e diff erence 
between the tumor markers was statistically sig-
nifi cant for p <0.05 according Student t-test. Th e 
coeffi  cient of correlation was r = 0.75, so we have 
good found correlation between CA 15-3 and CEA.
FIGURE 2.  The mean concentration of CEA. CA 15-3 and 
ferritin in patients with tumor and benign disease 
FIGURE 3.  Comparison of CA 15-3 and ferritin in serum measured by Architect CMIA. The correlation coeffi cient r = 0.274.
FIGURE 4.  Comparison of CA 15-3 and CEA in serum measured by Architect CMIA. The correlation coeffi cient r = 0.75.
142 JOURNAL OF HEALTH SCIENCES 2012; 2 (2)
NAFIJA  SERDAREVIĆ, SAMIRA MEHANOVIĆ: THE POSSIBLE ROLE OF TUMOR ANTIGEN CA 15-3, 
CEA AND FERRITIN IN MALIGNANT AND BENIGN DISEASE 
Discussion
Th e results of this study indicate that of the three 
tumor markers tested, serum CA15-3 is the most 
sensitive and specifi c in terms of the detection of 
breast cancer metastases. In our study the average 
concentration of CEA and CA 15-3 was higher 
in patients group with primary breast cancer, a 
results are shown in Figure 2. Th e CA 15-3 was 
higher in breast cancer but lower than CEA in 
lung cancer. Th e patients with mastitis diagno-
sis the have higher concentration of CA 15-3 but 
normal concentration of CEA. Serum CA15-3 
has been one of the most reliable tumor mark-
ers used in monitoring breast cancer patients. It 
has been reported that the sensitivity and speci-
fi city of serum CA15-3 for detecting metastatic 
diseases are higher than those of CEA (12,13). 
In our study the concentration of CEA was mostly 
elevated in patients with breast and lung carci-
noma. Th e recent study has reported that serum 
levels of CEA were high at patients with adeno-
carcinoma and squamous carcinoma (14). Th e 
other investigator has shown that CEA is sig-
nifi cantly related to diff erential degree of lung 
cancers (15). Th e diff erent staining patterns and 
positive rates and intensities of CEA may be 
helpful for the pathological classifi cation of lung 
cancers. Th e CEA concentration was in refer-
ence rage in patients with mastitis and controls. 
In this study patients with cancer particularly with 
lung cancer have higher concentration of ferri-
tin. Th is might be due to the potential additional 
regulators involved in ferritin synthesis. Iron is 
the main, but not the only regulator of ferritin 
expression. Hypoxia, oft en present in neoplas-
tic tissue, is also one of the factors that promote 
ferritin increase independently of the iron status 
(16, 17). Th e ferritin concentrations may be a 
prognostic indicator in some patients with lungs 
and breast cancer. In this study the highest levels 
of ferritin were obtained in the group of patients 
with advanced disease, which was in agreement 
with previous reports (18). Th e other study groups 
have found that ferritin has been previously asso-
ciated with breast cancer. Still, there is no consis-
tent conclusion regarding its role or relevance in 
breast cancer (19). Th e possible limitation of our 
study is that we do not have information about 
ferritin level in patients before cancer or mastitis.
Linear regression analysis of the values for the tu-
mor markers revealed that serum CA 15-3 values 
were not correlated with serum ferritin values (r = 
0.274) but it was good correlation with serum CEA 
values (r =0.750). Th e correlation results are shown 
in Figure 3 and 4. In other investigation groups it 
was found that good correlation between CA 15-3 
and CEA with coeffi  cient of correlation r = 0.96 (20).
Conclusion
Serum concentrations of CEA, CA 15-3, are re-
lated to tumor extent, with signifi cantly higher 
values seen in patients with breast cancer. Th e 
CA 15-3 is only specifi c in patients with metas-
tasis because we have got high concentration in 
patients with mastitis. Th e serum value of CEA 
was higher in patients with lung cancer. Further 
prospective studies, of a large number of subjects 
premenopausal and postmenopausal women, 
are required to confi rm such a statement and to 
validate the usefulness of ferritin determination 
in the serum of lung or breast cancer patients.
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